| __timestamp | Geron Corporation | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 20707000 | 100244000 |
| Thursday, January 1, 2015 | 17831000 | 29674000 |
| Friday, January 1, 2016 | 18047000 | 14917000 |
| Sunday, January 1, 2017 | 11033000 | 14118000 |
| Monday, January 1, 2018 | 13432000 | 8737000 |
| Tuesday, January 1, 2019 | 52072000 | 6900000 |
| Wednesday, January 1, 2020 | 51488000 | 6248000 |
| Friday, January 1, 2021 | 85727000 | 12312000 |
| Saturday, January 1, 2022 | 95518000 | 19721000 |
| Sunday, January 1, 2023 | 125046000 | 31283000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Geron Corporation and MannKind Corporation have been at the forefront of this race, each investing significantly in research and development (R&D). From 2014 to 2023, Geron Corporation has consistently increased its R&D spending, culminating in a remarkable 500% increase by 2023. In contrast, MannKind Corporation's investment peaked in 2014, with a notable decline thereafter, reaching just 31% of its 2014 levels by 2023.
This trend highlights Geron's commitment to innovation, as it outpaces MannKind in R&D investment by a ratio of 4:1 in recent years. As the biotech industry continues to evolve, these strategic investments could be pivotal in determining which company leads the next wave of medical breakthroughs.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.